Tempus Phoenix Hnscc Study: A Longitudinal Multi-Omic Biomarker Profiling Study Of Patients With Head & Neck Squamous Cell Carcinoma (Hnscc)
Posted Date: Nov 12, 2024
- Investigator: Christopher Lemmon
- Specialties: Head and Neck Cancer, Oncology
- Type of Study: Observational/Survey
The study is a prospective, longitudinal, non-interventional, multicenter study of participants with HNSCC who will have tissue and blood based molecular biomarker profiling during their standard of care treatment.
Criteria:
Inclusion Criteria: =18 Years Of Age Willing And Able To Provide Informed Consent Histologically- Or Cytologically-Confirmed Metastatic Or Unresectable, Recurrent Hnscc Unsuitable For Local Therapies Intended For First Line Anti-Pd1 Or Pdl1 Monotherapy Or Combination Therapy Must Submit Tumor Tissue Sample Representative Of Current Disease Per Laboratory Manual Exclusion Criteria: Non-Squamous Histologies (Eg, Nasopharynx Or Salivary Gland) Relapse Or Recurrence Within 6 Months Of First Line Chemotherapy And / Or Chemoradiotherapy Tumors That Are Pd-L1 Negative (Cps <1) Clinical Evidence Of An Active Second Invasive Malignancy Within <2 Years Of Enrollment With The Exception Of Stable Prostate Cancer On Watchful Waiting, In Situ Cervical Cancer, In Situ Breast Carcinoma Or Localized Non-Melanoma Skin Cancers Unable To Comply With Study Procedures (I.E., Not Willing Or Able To Have Additional Blood Samples Collected)
Keywords:
Hnscc, Genomic Profiling, Ngs
For More Information:
Ilaina Monroe
NULL
cancer@uchealth.com